The FDA approved a combination of the PARP inhibitor niraparib with a hormone therapy agent plus a corticosteroid for certain patients with metastatic prostate cancer. The U.S. Food and Drug Administration (FDA) has approved...
Lisocabtagene maraleucel was granted approval for adults with treatment-resistant marginal zone lymphoma. The U.S. Food and Drug Administration (FDA) has approved lisocabtagene maraleucel (Breyanzi) for adults with relapsed or refractory marginal zone lymphoma (MZL)...
Pirtobrutinib was approved for certain relapsed/refractory chronic lymphocytic leukemias or small lymphocytic lymphomas. The U.S. Food and Drug Administration (FDA) has granted traditional approval to pirtobrutinib (Jaypirca) for adults with relapsed or refractory chronic...
Durvalumab was approved as neoadjuvant and adjuvant treatment with chemotherapy for resectable gastric or gastroesophageal junction cancer. The U.S. Food and Drug Administration (FDA) has approved durvalumab (Imfinzi) as a neoadjuvant and adjuvant therapy...
The combination therapy is approved for pre- and post-surgery bladder cancer treatment. The U.S. Food and Drug Administration (FDA) has approved a combination therapy that uses either pembrolizumab (Keytruda) or pembrolizumab and berahyaluronidase alfa-pmph...
The FDA has converted the accelerated approval of tarlatamab-dlle to a full approval for previously treated adults with extensive-stage small cell lung cancer. The U.S. Food and Drug Administration (FDA) has granted traditional approval...
The FDA granted accelerated approval to sevabertinib for previously treated adults with HER2‑mutant non‑squamous non‑small cell lung cancer. The U.S. Food and Drug Administration (FDA) has granted accelerated approval to sevabertinib (Hyrnuo) for the...
Daratumumab and hyaluronidase-fihj is now indicated as part of a combination therapy for the potentially fatal condition that can develop in patients with multiple myeloma. The U.S. Food and Drug Administration (FDA) has granted...
FDA expands selumetinib approval to include treatment of adults with inoperable plexiform neurofibromas. The U.S. Food and Drug Administration (FDA) has approved selumetinib (Koselugo) for adults with neurofibromatosis type 1 (NF1) who have symptomatic,...
The FDA approved epcoritamab-bysp as a monotherapy or with lenalidomide and rituximab for relapsed or refractory follicular lymphoma. The U.S. Food and Drug Administration (FDA) has approved epcoritamab-bysp (Epkinly) with lenalidomide (Revlimid) and rituximab...
AACR Fellow Lewis C. Cantley, PhD, leads a national effort targeting triple-negative breast cancer and ovarian cancer with a novel drug combination.
Learn More